Regency Therapeutics, a division of Luitpold Pharmaceuticals, and Daiichi-Sankyo, Inc. have announced the launch of Sprix ketorolac tromethamine nasal spray “for the short-term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.” The US FDA approved Sprix in May 2010. In December 2010, Luitpold, a subsidiary of Daiichi Sankyo Co., Ltd, acquired Roxro Pharmaceuticals, which had developed Sprix.
“We are pleased to be able to provide healthcare professionals with an important new non-opioid analgesic to treat moderate to moderately severe acute pain. We believe that SPRIX® (ketorolac tromethamine) Nasal Spray will be highly complementary to Luitpold’s existing product line and our continuing strategy to diversify our product portfolio and further grow our U.S. pharmaceutical business,” commented Mary Jane Helenek, Luitpold President and CEO.
Read the Regency and Daiichi-Sankyo press release.
